Journal of clinical medicine research

Use of GLP-1 and GIP/GLP-1 Drugs and Other Blood Sugar Medicines Needing Careful Use in Older Japanese People with Type 2 Diabetes

Updated

Abstract

Essence

GLP-1 receptor agonists were commonly used alongside other caution-requiring glucose-lowering drugs in elderly Japanese outpatients with .

Evidence

This single-center retrospective cross-sectional descriptive study reviewed electronic records for 214 outpatients aged 65 years or older with type 2 diabetes treated between September and December 2025.

Caveat

The study was exploratory, single-center, and descriptive, so it reports prescribing patterns rather than adverse events or clinical outcomes.

Simplified

Key numbers

50 of 214
GLP-1RA Prescription Rate
Total number of elderly patients with included in the study.
3.2 ± 0.8
Concomitant GLDs
Mean number of glucose-lowering drugs prescribed to GLP-1RA users.
63.0%
Obesity Prevalence
Percentage of GLP-1RA users classified as having obesity.

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

M. Sato is full-time employee of Nippon Boehringer Ingelheim Co., Ltd. and shareholders of Eli Lilly and Company. T. Saika and M. Yamazaki are full-time employees of KAKEHASHI Inc. M. Sato, T. Saika, and M. Yamazaki state that the opinions expressed in this work are solely their own and do not represent the views of their current employers. M. Sakamoto has received lecture fees from Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corporation, Sanofi K.K., MSD K.K., Daiichi Sankyo Co., Ltd. and Nippon Boehringer Ingelheim Co., Ltd. and has also received a consulting fee from KAKEHASHI Inc. T. Yamazaki, R. Takemura and M. Yuki declare no conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free